Revenue
2021
2022
2023
2024
2025
Virax Biolabs Group Ltd (VRAX)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6,331 | $156,419 | $8,561 | $0 | $123,820 |
| Gross profit | −$53,067 | $50,590 | −$1,365 | — | −$9,434 |
| Research & development | $1.8M | $1.6M | $2.2M | $433,743 | $120,221 |
| Operating expenses | $6.1M | $6.5M | $5.7M | $1.7M | $635,104 |
| Operating income | −$6.2M | −$6.5M | −$5.7M | −$1.7M | −$644,538 |
| EBITDAderived | −$5.9M | −$6.4M | — | — | — |
| Net income | −$6.1M | −$6.7M | −$5.5M | −$1.7M | −$650,984 |
| Basic EPSper diluted share | -$1.62 | -$3.36 | -$5.13 | -$1.79 | — |
| Diluted EPSper diluted share | -$1.62 | -$3.36 | -$5.13 | -$1.79 | — |